Modality
mAb
MOA
Cl18.2
Target
SGLT2
Pathway
Hedgehog
CholangiocarcinomaMyelofibrosis
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
Sep 2019
→ May 2028
Phase 2Current
NCT07392078
216 pts·Myelofibrosis
2019-09→2028-05·Active
216 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-032.1y awayPh3 Readout· Myelofibrosis
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Active
Catalysts
Ph3 Readout
2028-05-03 · 2.1y away
Myelofibrosis
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07392078 | Phase 2/3 | Myelofibrosis | Active | 216 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 |